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Abstract
Background. This study aimed to investigate general factors associated with prognosis regard-
less of the type of treatment received, for adults with depression in primary care.
Methods. We searched Medline, Embase, PsycINFO and Cochrane Central (inception to 12/
01/2020) for RCTs that included the most commonly used comprehensive measure of depres-
sive and anxiety disorder symptoms and diagnoses, in primary care depression RCTs (the
Revised Clinical Interview Schedule: CIS-R). Two-stage random-effects meta-analyses were
conducted.
Results. Twelve (n = 6024) of thirteen eligible studies (n = 6175) provided individual patient
data. There was a 31% (95%CI: 25 to 37) difference in depressive symptoms at 3–4 months per
standard deviation increase in baseline depressive symptoms. Four additional factors: the dur-
ation of anxiety; duration of depression; comorbid panic disorder; and a history of antidepres-
sant treatment were also independently associated with poorer prognosis. There was evidence
that the difference in prognosis when these factors were combined could be of clinical import-
ance. Adding these variables improved the amount of variance explained in 3–4 month
depressive symptoms from 16% using depressive symptom severity alone to 27%. Risk of
bias (assessed with QUIPS) was low in all studies and quality (assessed with GRADE) was
high. Sensitivity analyses did not alter our conclusions.
Conclusions.When adults seek treatment for depression clinicians should routinely assess for
the duration of anxiety, duration of depression, comorbid panic disorder, and a history of
antidepressant treatment alongside depressive symptom severity. This could provide clinicians
and patients with useful and desired information to elucidate prognosis and aid the clinical
management of depression.
Introduction
Depression is a burdensome disease with a high prevalence, affecting one in 20 adults at any
one time (Thornicroft et al., 2017). Not reaching full remission after initial treatment is a
strong predictor of poor long-term prognosis including relapse and recurrence of depression
(Buckman et al., 2018b; Judd et al., 2000). Knowledge of factors associated with prognosis can
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be useful for patients and clinicians informing the content of routine
clinical assessments and decisions regarding the future clinical man-
agement of the patient’s condition, and providing them with infor-
mation they want to know (Trusheim, Berndt, & Douglas, 2007).
There have been a number of different approaches towards
studying prognosis. For adults with depression, it has most com-
monly been studied in systematic reviews or randomised con-
trolled trials (RCTs) that have focused on prognosis for those
receiving a single treatment – typically, an antidepressant or cog-
nitive behavioural therapy (Bower et al., 2013a, b; Chekroud et al.,
2016; Driessen, Cuijpers, Hollon, & Dekker, 2010; Karyotaki et al.,
2017). Such studies might identify a mixture of general prognostic
factors applicable regardless of treatment type and prognostic fac-
tors unique to that treatment modality, but due to their design,
they cannot distinguish between the two. For example, the pre-
dictive models from STAR*D that examined outcomes on the
antidepressant citalopram were found to generalise to escitalo-
pram–bupropion but not to venlafaxine–mirtazapine (Chekroud
et al., 2016). At the outset of treatment, it is impossible to
know what future treatments a patient will receive so general
information about prognosis, that would apply to all treatments,
is of clinical value (Hippisley-Cox et al., 2007; Trusheim et al.,
2007); this can be called ‘prognosis independent of treatment’.
Another approach to studying prognostic factors is to identify
people with depression from cohort studies. Most cohorts have
small numbers of people with depression and many have not
sought treatment (Buckman et al., 2018b; Hardeveld, Spijker,
De Graaf, Nolen, & Beekman, 2009). Therefore, inferences about
prognosis from these samples can be imprecise and might not be
generalisable to the population of help-seeking patients who are
seen by clinicians. The approach taken in the current study is to
examine data from the individual participants of a wide range of
RCTs that have investigated a breadth of pharmacological, psycho-
logical and other interventions, amongst individuals seeking treat-
ment for depression, and to partial out the effects of the
randomisation in each study, to investigate the associations between
patient characteristics and prognosis. In theory, depending on the
breadth of the treatments used in the contributing studies, this
approach allows for the investigation of prognostic factors that
apply to any course of treatment and should therefore be more gen-
eralisable to a wider range of clinical circumstances.
Meta-analyses of individual patient data (IPD) collected from
RCTs can provide an improved understanding of factors asso-
ciated with prognosis independent of treatment (Bower et al.,
2013a, b; Driessen et al., 2010; Gibbons, Hur, Brown, Davis, &
Mann, 2012) as they are able to deliver greater power and there-
fore more precise estimates than individual studies or study-level
meta-analyses (Driessen et al., 2010; Fisher, Carpenter, Morris,
Freeman, & Tierney, 2017; Stewart et al., 2015). A meta-review
of systematic reviews and meta-analyses, including IPD
meta-analyses, was conducted to inform the methods and focus
of the current study (online Supplementary Tables 1 and 2).
That meta-review established that there is strong evidence of an
association between the severity of depressive symptoms pre-
treatment and prognosis with particular treatments (Bower
et al., 2013a, b; Driessen et al., 2010; Weitz et al., 2015).
However, there is uncertainty over the strength and the clinical
importance of the association due to a lack of reporting of effect
sizes (Chekroud et al., 2016; Noma et al., 2019), and wide confi-
dence intervals (CIs) in the studied effects (Fournier et al., 2010;
Johnsen & Friborg, 2015; Weitz et al., 2015). As noted above,
there is also the possibility that these associations are limited to
patients receiving particular type of treatment only, given the
focus of past studies (Bower et al., 2013a, b; Driessen et al.,
2010; Karyotaki et al., 2017). As such, the current evidence may
not be useful for clinicians wanting to inform patients of their
prognosis before a decision has been made regarding the type
of treatment to start, or in settings where the particular treatments
studied are not available.
The meta-review identified a number of other potential prog-
nostic factors, including life events, social support and socio-
demographics which are beyond the scope of the current study
(Buckman et al., 2021), and several others which are related to
the severity of the mental health problem a patient with depres-
sion might present with in a clinic. These severity-related factors
can be referred to as depressive ‘disorder characteristics’, in con-
trast to depressive ‘symptom severity’. Some of these ‘disorder
characteristics’ such as duration and comorbidity with anxiety
have been reported to be associated with response to a particular
treatment [e.g. citalopram in STAR*D (Chekroud et al., 2016)],
but there have been inconsistent findings and most studies did
not adjust for depressive symptom severity (Johnsen & Friborg,
2015; Nakabayashi, Hara, & Minami, 2018; Noma et al., 2019).
One study has found an interaction between duration and symp-
tom severity suggesting that considerations of prognosis should
not be limited to symptom severity alone (Lorenzo-Luaces,
Rodriguez-Quintana, & Bailey, 2020). However, that was a study
of adolescents, in a single sample, with two treatment types, their
combination, or placebo, and was not able to consider a broader
spectrum of depressive ‘disorder characteristics’. Previous studies
have also rarely included data from primary care settings, or pro-
vided insufficient information about how participants were
recruited to know if the results are generalisable to other health
care settings. Large proportions of adults seeking treatment for
depression present in primary care (Olfson, Blanco, & Marcus,
2016; Thornicroft et al., 2017), so identifying prognostic factors in
a primary care setting has important utility.
This study aimed to provide clinically useful estimates for
prognostic factors that would apply whatever treatment a patient
would receive. The specific aims were to investigate: (1) the degree
to which depressive symptom severity is associated with prognosis
for adults with depression in primary care, independent of treat-
ment type; and (2) which depressive ‘disorder characteristics’ are
associated with prognosis independent of treatment type, and
independent of depressive symptom severity.
Methods
This study involved compiling an IPD from RCTs of adults with
depression that sought treatment in primary care. In order to
thoroughly investigate the association between depressive ‘dis-
order characteristics’ and prognosis a measure that captures a
comprehensive set of such clinical features is required. Scoping
searches were conducted to identify the most commonly used
measure of this type in RCTs that recruited adults with depression
in primary care; we established that this was the Revised Clinical
Interview Schedule (CIS-R) (Lewis, Pelosi, Araya, & Dunn, 1992).
The CIS-R is a measure commonly used in RCTs and epidemio-
logical studies that has been translated into many languages
(McManus, Bebbington, Jenkins, & Brugha, 2016; Subramaniam,
Krishnaswamy, Jemain,Hamid, &Patel, 2006). It is used tomeasure
symptoms and make diagnostic determinations of depressive
and anxiety disorders in line with criteria from the International
Classification of Diseases 10th edition (World Health
2 Joshua E. J. Buckman et al.
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0033291721001367
Downloaded from https://www.cambridge.org/core. IP address: 91.125.222.7, on 15 Apr 2021 at 09:58:55, subject to the Cambridge Core terms of use, available at
Organization, 1992). CIS-R is most commonly administered via a
computerised program such that lay personnel can conduct the
interviews, reducing clinical time and cost (Subramaniam et al.,
2006). The use of this measure at baseline was made an inclusion
criterion for the searches in order to minimise bias in harmonising
data across RCTs. The methods for this systematic review and IPD
meta-analysis were pre-registered (Buckman et al., 2020)
[PROSPERO: CRD42019129512 (01/04/2019)]; for details of
protocol amendments and derivations, see online Supplementary
materials.
Identification and selection of studies
Studies were identified via searches on Medline, Embase,
PsycINFO and Cochrane Central (inception to 1st December
2020), hand-searching of reference lists, and contacting experts
for unpublished or missed studies. Full details of the searches
are provided in online Supplementary Table 3.
Inclusion and exclusion criteria
Studies were included if they: were RCTs of adults (aged ⩾16
years) with unipolar depression, or with depressive symptoms sig-
nificant enough for them to seek treatment, or a CIS-R (Lewis
et al., 1992) score of ⩾12 (the usual case definition for a common
mental disorder); recruited from primary care; had at least one
active treatment arm; and used the CIS-R at baseline.
Studies were excluded if they were studies of: patients with
depression secondary to a diagnosis of personality disorder,
psychotic conditions or neurological conditions; bipolar or psych-
otic depressions; children or adolescents; feasibility or were stud-
ies of adults with either depression or an anxiety disorder, rather
than a primary depression with or without comorbid anxiety.
See Table 1 for details of the included studies.
Measures
The measures of depressive symptoms used to determine depres-
sive ‘symptom severity’ and outcomes are noted in Table 1; details
of all measures are given in online Supplementary Table 4.
Ethical considerations and trial registrations
All included studies were granted ethical approvals and all parti-
cipants gave informed consent (online Supplementary Table 5).
No additional NHS ethical approval was required for this study:
HRA reference 712/86/32/81.
Data analysis plan
Details on determining study inclusion, data extraction, data
handling and data management, risk of bias and study quality,
secondary outcomes and sensitivity analyses, and results from
these, are provided in online Supplementary materials.
Primary outcomes
The primary outcome was depressive symptoms at 3–4 months.
This was captured in two ways: (1) z-score (standardised mean)
of the scores on the four depressive symptom measures used at
3–4 months post-baseline in each study (Table 1). The score at
3–4 months was divided by the standard deviation for that meas-
ure calculated at 3–4 months. (2) The logarithm of depression
scale scores irrespective of the measure used. Exponentiation of
the regression coefficient provides an estimate of the percentage
difference in symptoms.
It was expected that these methods would give broadly similar
results but that the log outcome might have greater clinical utility
as percentage differences might be more easily understood and do
not require division by standard deviation estimates.
Prognostic indicators under consideration
(1) Depressive symptom severity at baseline taken as scores on
the depressive symptom measures is detailed in Table 1.
(2) Depressive ‘disorder characteristics’:
• the sum of the scores on the CIS-R anxiety subscales, and each
individual subscale
• the number of comorbid common mental health disorders
(CMDs), and each individual disorder
• the duration of depression
• the duration of anxiety individually and averaged across CIS-R
anxiety subscales
• a history of depression
• a history of any previous treatment for depression
• a history of antidepressant treatment
• the degree of functional impairment
• alcohol misuse
Primary analyses
Two-stage random effects meta-analyses were conducted for each
prognostic factor. This approach removes variance due to the dif-
ferent depressive symptom measures used across the studies,
removes potential biases by separating within-study from
between-study effects, and allows for more simple formations of
forest plots and hence for the assessment of heterogeneity than
one-stage approaches (Fisher, 2015; Fisher et al., 2017). It does
so by analysing effects within each study first, before aggregating
across studies. One-stage approaches have been favoured in other
IPD meta-analyses as they allow for more complex modelling
(Cuijpers et al., 2014; Weitz, Kleiboer, Van Straten, Hollon, &
Cuijpers, 2017). However, as no complex modelling was necessary
here, the two-stage approach was most suitable for the aims of the
current study (Fisher, 2015).
There were three sets of variables adjusted for in models of
each outcome built for each prognostic factor:
(1) The ‘disorder characteristic’ adjusted for age, gender and the
specific randomised treatment(s) in each study.
(2) As in (1) with the addition of depressive symptom severity.
(3) As in (2) with the addition of covariates specific to each prog-
nostic indicator.
Covariates were added to the models above if they were: inde-
pendently associated with the outcome and prognostic indicator;
not multi-collinear with prognostic indicators in the model; not
systematically missing and if they impacted the effect estimate
for the association between prognostic indicator and outcome
when included compared to when excluded from the model.
Two factors considered a priori to be important covariates (age
and gender) were controlled for in all models.
Final models were built with the primary outcomes adding
each prognostic indicator to the model in order of magnitude
of effect from model 3 (one-by-one), and removing those no
longer significantly associated with prognosis (at the 5% signifi-
cance level) after adding subsequent factors. If two items were
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327 Y Adults with new depressive
episodes diagnosed by GP
43.1 (15.4) 67 HADS
depression =
10.5 (3.9)





527 Y Adults ⩾18, ICD-10 depressive
episode
44.4 (13.2) 72 PHQ-9 = 17.7
(5.1)





469 Y Adults 18–75 with treatment
resistant depression, scoring ⩾14
BDI-II
49.6 (11.7) 72 BDI-II = 31.8
(10.7)




601 N Adults 18–74 with depressive
episode








609 Y Adults ⩾18, PHQ-9 score ⩾10,
confirmed diagnosis of
depression with CIS-R, internet
access
49.5 (12.9) 69 PHQ-9 = 16.9
(4.6)





295 Y Adults scoring ⩾14 BDI-II and GP
confirmed diagnosis of
depression
34.9 (11.6) 68 BDI-II = 33.2
(8.8)
34 iCBT + TAU v. TAU +









MIR (Kessler et al.,
2018)
480 Y Adults ⩾18 taking SSRIs or SNRIs
at adequate dose for ⩾6 weeks,
and scored ⩾14 on BDI-II
50.7 (13.2) 69 BDI-II = 31.1
(9.9)




652 Y Adults presenting with low mood
or depression to GP in last 2
years, free of ADM for 8 weeks up
to baseline
39.7 (15.0) 59 BDI-II = 23.9
(10.3)




685 Y Adults with PHQ-9 ⩾10
presenting to GP with depression
39.9 (12.7) 67 PHQ-9 = 16.7
(4.3)
53 Moodgym v. beating




220 Y Women meeting criteria for MDD
within 6-months post-partum
28.7 (6.4) 100 EPDS = 17.6
(3.4)





361 Y Adults 18–69 who met diagnostic
criteria for MDD and scored ⩾14
on BDI-II
39.8 (12.6) 66 BDI-II = 32.1
(9.2)
35 Physical activity + TAU
v. TAU
BDI-II
ADM, antidepressant medication; BDI-II, Beck Depression Inventory; EPDS, Edinburgh Postnatal Depression Scale; GHQ-12, General Health Questionnaire 12 item version; HADS-D, Hospital Anxiety and Depression Scale-depression subscale; iCBT,
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highly collinear the one contributing least to the model was re-
moved. In the final models, ordinal variables were re-categorised
to assess the associations with prognosis in clinically meaningful
groups (e.g. duration items were re-categorised into durations
at baseline of less than or equal to 1 year, and greater than
1 year). The explanatory utility of the final models was assessed
by considering the amount of variance in depressive symptom
scale scores at 3–4 months explained by the models when adding
each variable one-by-one, using the adjusted R2 statistic; for
details of how this was calculated see online Supplementary
materials.
Meta-analyses were conducted using DerSimonian and Laird
random effects models with the ‘ipdmetan’ package in Stata
(Fisher, 2015). For the z-score and log outcomes at 3–4 months
and 6–8 months (secondary outcome) linear regression models
were fitted. Logistic models were fitted for remission (secondary
outcome). The degree of heterogeneity was assessed using predic-
tion intervals and its impact was assessed using the I2 statistic
(Higgins, Thompson, Deeks, & Altman, 2003).
Results
Characteristics of the included studies
In total, 13 RCTs met inclusion criteria (Fig. 1). Data were not
available for one study (Mynors-wallis, Gath, Day, & Baker,
2000). Descriptions of the included studies are given in Table 1.
Risk of bias was low in all studies and quality was rated as high
(online Supplementary Tables 6 and 7).
A key question in this study was whether or not adjusting for
depressive symptom severity ameliorates the associations between
depressive ‘disorder characteristics’ and prognosis independent of
treatment, therefore descriptive statistics are presented stratified
by a median split of depressive symptom severity (Table 2).
Means and standard deviations in each strata are presented across
all studies. Those with higher depressive symptom severity were
more likely to have: identified as female; more comorbid mental
health problems; longer durations of their mental health pro-
blems; lower social support; lower health-related quality of life;
more adverse life events and greater social disadvantages, than
those with lower baseline scores (Table 2).
The association between depressive symptom severity and
prognosis independent of treatment
Overall, depressive symptom severity was strongly associated with
prognosis at 3–4 months post-baseline. On average, scores at 3–4
months were approximately 31% higher per standard deviation
increase in depressive symptoms at baseline (Table 3).
Associations between each potential depressive ‘disorder
characteristic’ and prognosis
All depressive ‘disorder characteristics’ studied here were asso-
ciated with prognosis at 3–4 months post-baseline independent
of treatment, apart from a comorbid diagnosis of specific phobias,
and hazardous alcohol misuse (Table 3). However, after adjust-
ment for baseline depressive symptom severity, there was only evi-
dence of a few ‘disorder characteristics’ being associated with
prognosis. Patients with longer durations of depression or of anx-
iety had poorer prognoses than those with shorter durations.
Similarly, patients with a history of depression or treatment for
depression had poorer prognoses than those without such histories.
However, there was no evidence that functional impairment or
most comorbid diagnoses were associated with prognosis after adjust-
ing for depressive symptom severity and covariates (model 3), with
the exception of Chronic Fatigue Syndrome, and Panic Disorder.
Findings were consistent when using the z-score and log out-
comes with one exception in model 3: using the z-score there was
some evidence that each of the three variables capturing history of
depression were associated with prognosis, but no such evidence
when using the log outcome.
Independent associations between depressive ‘disorder
characteristics’ and prognosis
Many ‘disorder characteristics’ were missing in two studies
(Kendrick et al., 2006; Salisbury et al., 2016). The difference
when including or excluding those studies on the effects of vari-
ables that were not systematically missing in any study were neg-
ligible, see online Supplementary materials. These studies were
therefore removed from further primary analyses.
There was only evidence of an association with prognosis for
six ‘disorder characteristics’ after adjusting for treatment, depres-
sive symptom severity, covariates and other ‘disorder characteris-
tics’ (online Supplementary Fig. 1). The associations for these six
factors were similar across studies with potentially different popu-
lations, e.g. in those with ‘treatment resistant depression’
(COBALT), those with apparently less severe depression at base-
line (PANDA) and those with postnatal depression (RESPOND);
see online Supplementary Fig. 1.
Four ‘disorder characteristics’ were included in the final mod-
els in addition to depressive symptom severity (Table 4): duration
of depression, average duration of anxiety symptoms, comorbid
panic disorder and a history of antidepressant treatment.
Although the latter was only significantly associated with progno-
sis when using the z-score outcome, when removing two studies
with little variability in this factor due to their inclusion criteria
(COBALT and MIR – see Table 1) there was greater evidence
for an effect with the log outcome: 6.3% (95% CI: 0.3–12.7). It
is noteworthy too that there was 0% heterogeneity in this effect,
so there were no substantive differences in the association for
studies that randomised to antidepressant treatments and those
that did not. The sum of the anxiety subscale scores on CIS-R,
and a history of any previous treatment for depression could be
included in the final model in place of the average duration of
anxiety and a history of antidepressant treatment, respectively,
although had weaker associations with outcomes than those
retained in the final models (online Supplementary Table 12).
Patients that had durations of depression and anxiety greater
than 1 year, had comorbid panic disorder and a history of anti-
depressant treatment, i.e. those in the ‘high severity’ category on
the above variables (n = 220), had on average 36.3% (95% CI:
12.4–65.2) higher scores at 3–4 months than patients with none
of the above (n = 707). Adding all four ‘disorder characteristics’
to models in addition to depressive symptom severity led to sub-
stantial gains in the variance explained in the primary outcomes,
which increased with each factor added (online Supplementary
Table 10).
Discussion
In this systematic review with IPD meta-analyses it was found that
depressive symptom severity was strongly associated with
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prognosis independent of treatment. Depressive symptom scale
scores were on average 31% higher at 3–4 months, 33% higher
at 6–8 months and the odds of remission at 3–4 months were
approximately halved, for every standard deviation increase in
baseline depressive symptoms. Absolute differences were also
assessed: for every 11-point increase in BDI-II scores at baseline,
scores were about 7 points higher at 3–4 months on average, and
for the studies that used the PHQ-9 for each 5-point increase at
baseline scores approximately 5 points higher at 3–4 months.
Nearly all ‘disorder characteristics’ were associated with
prognosis independent of treatment but only a handful were
associated with prognosis independent of depressive symptom
severity. This illustrates the importance of adjusting for base-
line depression symptom severity when investigating prognosis
of depression. The factors independently associated with prog-
nosis were: duration of depression; average duration of anxiety
(or severity of anxiety symptoms); comorbid panic disorder
and a history of antidepressant treatment (or history of any
treatment for depression). The history of treatment variables
were not as consistently associated with outcomes as the
other factors we identified and the association was relatively
small.
Fig. 1. Flowchart of studies through selection process for IPD meta-analysis.
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severity χ2 or t test
Self-reported baseline
characteristics Factor N (%) or mean (S.D.) N (%) or mean (S.D.) p value
Total 2978 (50) 3033 (50)
Age 44.0 (14.6) 41.4 (13.6) <0.0001
Gender Female 2005 (67%) 2127 (70%) 0.02
Male 973 (33%) 906 (30%)
Other 0 0
Ethnicity White 2262 (94%) 2319 (93%) 0.32
Non-White 143 (6%) 165 (7%)
Employment status Employed 1574 (50%) 1413 (49%) <0.0001
Not seeking employment 817 (29%) 749 (26%)
Unemployed 385 (14%) 739 (26%)
Marital status Married/cohabiting 1333 (55%) 1231 (47%) <0.0001
Single 663 (27%) 852 (32%)
No longer married 437 (18%) 557 (21%)
Educational attainment Degree or higher 691 (32%) 469 (23%) <0.0001
A-level or Diplomas 529 (25%) 518 (25%)
GCSE 634 (30%) 690 (33%)
None or other 289 (14%) 409 (20%)
Financial status Doing OK 957 (52%) 581 (32%) <0.0001
Just about getting by 573 (31%) 597 (33%)
Struggling 322 (17%) 616 (34%)
Housing status Home owner 1359 (56%) 1130 (44%) <0.0001
Tenant 789 (33%) 1126 (44%)
Other 263 (11%) 326 (13%)
Long-term conditions No 1653 (75%) 1773 (73%) 0.10
Yes 539 (25%) 646 (27%)
Social support Mean (S.D.) 21.3 (3.3) 19.2 (4.1) <0.0001
Number of recent life events Mean (S.D.) 1.4 (1.3) 1.8 (1.5) <0.0001
AUDIT-PC score Mean (S.D.) 2.8 (3.0) 2.7 (3.2) 0.71
Hazardous alcohol misuse No 1224 (79%) 1146 (78%)
Yes 327 (21%) 329 (23%) 0.41
EQ5D index score Mean (S.D.) 0.7 (0.2) 0.7 (0.2) <0.0001
History of depression No 815 (29%) 736 (23%) 0.0004
Yes 1995 (71%) 2415 (77%)
History of antidepressants No 1073 (38%) 1035 (33%) 0.0001
Yes 1739 (62%) 2120 (67%)
Any past treatment No 964 (39%) 940 (32%) <0.0001
Yes 1519 (61%) 1963 (68%)
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There was a lack of evidence for an independent association
between functional impairment and prognosis. Functional
impairment has been found to be indicative of treatment response
for people with either depression or anxiety disorders (Delgadillo,
Moreea, & Lutz, 2016; Saunders, Buckman, & Pilling, 2020;
Saunders, Cape, Fearon, & Pilling, 2016), so the single item
used to capture it here might be insufficient. There was also a
lack of evidence to support an association between hazardous
alcohol misuse and prognosis, this is in line with previous study
that has found it to be related to dropping out of treatment but
not to treatment outcomes apart from when patients are alcohol





severity χ2 or t test
Self-reported baseline
characteristics Factor N (%) or mean (S.D.) N (%) or mean (S.D.) p value
Functional impairment No impairment 344 (14%) 124 (5%) <0.0001
Things more difficult but get everything
done
1184 (49%) 902 (34%)
Impaired in one activity 376 (15%) 394 (15%)
Impaired in more than one activity 533 (22%) 1223 (46%)
Mean (S.D.) Mean (S.D.)
CIS-R scores Compulsions 0.6 (1.0) 1.0 (1.3) <0.0001
Concentration 1.7 (1.4) 2.4 (1.5) <0.0001
Depression 2.3 (1.2) 3.2 (1.0) <0.0001
Depressive thoughts 2.5 (1.4) 3.5 (1.1) <0.0001
Fatigue 3.0 (1.1) 3.3 (0.9) <0.0001
Generalised anxiety 1.8 (1.4) 2.5 (1.5) <0.0001
Health anxiety 0.8 (1.1) 1.3 (1.3) <0.0001
Irritability 2.0 (1.3) 2.6 (1.3) <0.0001
Obsessions 1.0 (1.5) 1.5 (1.7) <0.0001
Panic 0.4 (1.0) 1.0 (1.4) <0.0001
Phobias 0.9 (1.1) 1.5 (1.4) <0.0001
Sleep 1.9 (1.2) 2.6 (1.2) <0.0001
Somatic concerns 1.3 (1.4) 1.8 (1.4) <0.0001
Worry 2.1 (1.4) 2.8 (1.2) <0.0001
Compulsions 1.2 (1.8) 1.5 (1.9) <0.0001
Duration of symptoms (CIS-R) Concentration 2.6 (1.6) 3.1 (1.4) <0.0001
Depression 3.3 (1.4) 3. 5 (1.3) <0.0001
Fatigue 3.1 (1.4) 3.3 (1.3) <0.0001
Generalised anxiety 2.3 (1.9) 2.5 (1.9) 0.0001
Health anxiety 1.8 (1.9) 2.3 (1.9) <0.0001
Irritability 2.7 (1.6) 3.0 (1.5) <0.0001
Obsessions 1.2 (1.8) 1.7 (1.9) <0.0001
Panic 0.6 (1.4) 1.4 (1.9) <0.0001
Phobias 1.2 (1.9) 2.0 (2.1) <0.0001
Sleep 2.7 (1.8) 3.1 (1.6) <0.0001
Somatic concerns 2.3 (1.8) 2.7 (1.7) <0.0001
Worry 3.0 (1.6) 3.2 (1.4) <0.0001
Average anxiety duration 1.8 (0.9) 2.2 (1.0) <0.0001
Number of comorbid CMHDs 1.5 (1.0) 2.3 (1.1) <0.0001
Note: Numbers do not add up to total N due to missing data.
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Table 3. Outcomes at 3–4 months (‘mean difference’ in z-score of depressive symptoms, and percentage difference (%) in depressive symptoms) per unit increase in baseline prognostic indicators
Adjusted for treatment, age and gendera Additionally adjusted for depressive symptom severityb




(95% CI) I2 % (95% CI) I2
Mean difference
(95% CI) I2 % (95% CI) I2
Mean difference
(95% CI) I2 % (95% CI) I2
Depressive symptom
severity
0.44 (0.41–0.47) 16 30.7 (24.9–36.8) 78 0.44 (0.41–0.47) 16 30.7 (24.9–36.8) 78
CIS-R total score 0.04 (0.03–0.04) 23 13.1 (10.9–15.4) 62 0.02 (0.01–0.02) 48 6.2 (3.9–8.5) 50
Depressive subscales totald 0.09 (0.08–0.11) 71 27.7 (21.0–34.7) 69 0.04 (0.02–0.05) 40 10.0 (5.0–15.1) 42 0.03 (0.02–0.05) 46 8.2 (3.0–13.7) 45
Anxiety subscales totale 0.04 (0.03–0.05) 76 13.5 (10.0–17.1) 71 0.01 (0.01–0.02) 69 4.8 (1.8–8.0) 57 0.01 (0.00–0.02) 68 4.5 (1.4–7.7) 55
Compulsions score 0.13 (0.10–0.17) 44 8.9 (5.8–12.2) 61 0.05 (0.01–0.09) 59 3.6 (0.5–6.8) 63
Compulsions durationd 0.06 (0.04–0.09) 44 4.3 (2.5–6.2) 49 0.03 (0.00–0.05) 43 1.8 (0.1–3.5) 45 0.02 (0.00–0.04) 31 1.7 (0.2–3.3) 35
Concentration score 0.16 (0.11–0.20) 72 9.8 (6.5–13.3) 69 0.05 (0.02–0.07) 0 2.7 (1.0–4.5) 0
Concentration duration 0.12 (0.09–0.16) 62 8.2 (5.5–10.9) 61 0.06 (0.03–0.09) 49 4.0 (2.0–6.0) 37
Depression scoref 0.2 (0.15–0.25) 67 14.0 (10.6–17.5) 55 0.04 (0.01–0.08) 42 3.9 (1.4–6.4) 19 0.03 (−0.01 to 0.07) 42 3.1 (0.2–6.1) 22
Depressive thoughts scored 0.22 (0.18–0.25) 52 15.5 (12.2–18.9) 52 0.08 (0.06–0.11) 6 6.3 (3.9–8.8) 19 0.07 (0.04–0.10) 8 4.9 (2.5–7.4) 10
Depression durationd 0.15 (0.12–0.18) 27 10.2 (7.4–13.2) 51 0.09 (0.06–0.12) 49 6.6 (4.0–9.3) 49 0.08 (0.05–0.11) 46 5.9 (3.2–8.6) 49
Fatigue scored 0.09 (0.03–0.14) 70 6.6 (1.7–11.7) 74 0.03 (0.00–0.07) 30 3.2 (0.2–6.3) 37 0.03 (0.00–0.07) 21 3.2 (0.1–6.3) 31
Fatigue duration 0.12 (0.09–0.15) 35 8.1 (5.3–11.0) 52 0.08 (0.05–0.10) 28 5.7 (3.6–7.9) 25
Generalised anxiety scored 0.10 (0.07–0.13) 33 6.5 (4.4–8.7) 42 0.02 (0.00–0.04) 1 1.3 (−0.3 to 3.0) 7 0.02 (0.00–0.04) 13 1.5 (−0.2 to 3.2) 10
Generalised anxiety duration 0.06 (0.04–0.08) 0 4.4 (2.6–6.3) 32 0.03 (0.01–0.05) 0 2.5 (1.0–4.0) 14
Health anxiety scored 0.15 (0.12–0.18) 41 10.0 (8.0–12.1) 0 0.07 (0.04–0.10) 30 4.3 (2.2–6.5) 18 0.05 (0.02–0.08) 26 3.3 (0.9–5.7) 28
Health anxiety durationf 0.08 (0.06–0.09) 1 5.5 (4.2–6.8) 0 0.04 (0.02–0.05) 23 2.8 (1.6–4.0) 1 0.03 (0.01–0.04) 0 2.2 (1.0–3.4) 0
Irritability scoref 0.09 (0.06–0.11) 34 6.5 (4.5–8.5) 0 0.00 (−0.02 to 0.02) 0 0.7 (−1.3 to 2.7) 10 0.01 (−0.02 to 0.03) 9 1.2 (−0.8 to 3.2) 0
Irritability duratione 0.07 (0.04–0.10) 49 5.6 (3.3–8.1) 45 0.03 (0.00–0.06) 53 3.1 (0.8–5.4) 48 0.04 (0.01–0.07) 56 3.3 (0.9–5.7) 50
Obsessions score 0.06 (0.04–0.09) 41 3.5 (1.3–5.6) 52 0.01 (−0.02 to 0.04) 50 0.2 (−1.7 to 2.1) 47
Obsessions duration 0.05 (0.03–0.07) 0 3.0 (1.4–4.7) 35 0.01 (0.00–0.03) 17 0.7 (−0.8 to 2.2) 34
Panic scoree 0.13 (0.07–0.19) 82 8.6 (5.0–12.3) 72 0.05 (0.00–0.09) 72 3.1 (0.3–5.9) 55 0.05 (0.00–0.1) 74 3.1 (0.1–6.2) 59
Panic durationd 0.10 (0.08–0.13) 45 6.8 (4.7–8.9) 53 0.05 (0.02–0.07) 36 3.1 (1.4–4.8) 34 0.04 (0.02–0.06) 33 2.6 (1.0–4.3) 35
Phobias scored 0.15 (0.10–0.20) 75 10.0 (6.7–13.4) 62 0.06 (0.02–0.11) 64 4.1 (1.4–6.8) 46 0.04 (0.01–0.08) 53 2.9 (0.5–5.4) 32
Phobias durationf 0.08 (0.05–0.11) 70 5.6 (3.5–7.7) 63 0.03 (0.01–0.05) 56 2.3 (0.7–3.9) 40 0.02 (0.00–0.05) 52 1.9 (0.4–3.4) 35
Sleep scoref 0.13 (0.11–0.16) 25 8.3 (6.5–10.1) 45 0.04 (0.01–0.06) 1 2.6 (0.9–4.3) 0 0.02 (0.00–0.05) 10 1.8 (−0.2 to 3.8) 2
Sleep durationd 0.10 (0.08–0.13) 35 7.2 (5.1–9.2) 44 0.06 (0.03–0.09) 54 4.6 (2.5–6.7) 51 0.05 (0.03–0.08) 45 4.0 (2.1–6.0) 45
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Table 3. (Continued.)
Adjusted for treatment, age and gendera Additionally adjusted for depressive symptom severityb




(95% CI) I2 % (95% CI) I2
Mean difference
(95% CI) I2 % (95% CI) I2
Mean difference
(95% CI) I2 % (95% CI) I2
Somatic durationf 0.09 (0.07–0.11) 0 6.6 (5.2–8.1) 0 0.05 (0.04–0.07) 0 4.3 (2.9–5.7) 0 0.05 (0.03–0.06) 0 3.8 (2.5–5.2) 0
Worry scored 0.11 (0.08–0.14) 36 7.0 (4.9–9.2) 24 0.02 (−0.01 to 0.04) 18 0.9 (−0.8 to 2.7) 0 0.02 (−0.01 to 0.04) 6 0.8 (−1.0 to 2.7) 0
Worry duration 0.09 (0.07–0.11) 0 6.6 (4.6–8.6) 21 0.05 (0.03–0.07) 0 3.7 (2.0–5.4) 0
Average duration of anxietyf 0.26 (0.21–0.31) 58 19.6 (14.6–24.8) 67 0.13 (0.08–0.18) 53 10.3 (6.2–14.5) 51 0.11 (0.07–0.16) 45 9.2 (5.4–13.2) 47
Number of comorbid CMDsf 0.21 (0.12–0.29) 87 14.5 (8.5–20.8) 82 0.06 (0.00–0.12) 70 4.6 (0.6–8.7) 56 0.05 (−0.01 to 0.11) 72 4.1 (−0.0 to 8.3) 60
Agoraphobiad 0.34 (0.19–0.49) 51 25.7 (16.5–35.7) 11 0.14 (0.02–0.26) 30 10.4 (3.1–18.2) 0 0.09 (−0.03 to 0.20) 25 6.0 (−1.1 to 13.5) 0
CFSe 0.31 (0.20–0.43) 64 26.1 (15.6–37.5) 60 0.08 (0.00–0.15) 20 9.8 (4.0–15.9) 0 0.09 (0.01–0.17) 29 10.8 (4.8–17.2) 5
GAD 0.24 (0.18–0.31) 4 17.5 (12.0–23.4) 0 0.04 (−0.02 to 0.10) 0 4.0 (−0.8 to 9.1) 4
MADD −0.24 (−0.30 to −0.18) 54 −12.5 (−16.8 to −8.0) 59 −0.05 (−0.12 to 0.01) 0 −2.3 (−7.1 to 2.8) 28
OCD 0.34 (0.22–0.46) 30 21.5 (13.1–30.6) 9 0.01 (−0.10 to 0.12) 19 −1.3 (−9.2 to 7.3) 29
Panic disorder 0.41 (0.19–0.64) 72 33.1 (19.1–48.7) 48 0.21 (0.07–0.34) 34 15.0 (6.9–23.7) 0
Social phobia 0.24 (0.08–0.39) 55 18.3 (6.9–30.8) 47 0.10 (−0.02 to 0.22) 36 8.1 (−0.2 to 17.0) 20
Specific phobiasd 0.08 (−0.01 to 0.17) 0 6.3 (−0.0 to 13.0) 0 −0.04 (−0.12 to 0.04) 0 −1.2 (−6.8 to 4.9) 0 −0.02 (−0.10 to 0.06) 0 0.2 (−5.5 to 6.3) 0
History of depressionf 0.19 (0.12–0.26) 42 8.0 (2.7–13.5) 59 0.11 (0.05–0.17) 30 3.3 (−1.5 to 8.3) 55 0.09 (0.02–0.16) 13 2.6 (−2.6 to 8.2) 53
History of antidepressants 0.17 (0.10–0.25) 20 8.5 (1.9–15.5) 43 0.10 (0.03–0.17) 24 3.7 (−2.1 to 9.9) 40
Any past treatment 0.19 (0.13–0.26) 0 10.2 (3.9–17.0) 24 0.11 (0.05–0.18) 13 5.2 (−0.7 to 11.4) 26
Functional impairmentf 0.27 (0.15–0.39) 72 20.7 (11.3–30.9) 63 0.04 (−0.05 to 0.14) 58 4.6 (−2.4 to 12.0) 48 0.02 (−0.07 to 0.11) 54 2.8 (−3.9 to 9.9) 46
Hazardous alcohol misusee 0.06 (−0.06 to 0.19) 31 7.2 (−4.1 to 19.9) 45 0.01 (−0.09 to 0.10) 0 3.3 (−5.6 to 12.92 28 0.00 (−0.09 to 0.09) 0 2.7 (−5.9 to 12.0) 24
aAdjusted for treatment allocation, age and gender only.
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Findings in context
This study provides confirmation that depressive symptom sever-
ity is the strongest indicator of prognosis independent of treat-
ment. A number of other studies have found symptom severity
to be associated with outcomes but none have considered the
association independent of a broad range of commonly available
treatments in primary care settings. In addition, given the sample
size in this IPD meta-analysis this study was able to address the
question of the strength and the clinical importance of the asso-
ciation between symptom severity and prognosis with greater pre-
cision than has been possible in other studies (Fournier et al.,
2010; Johnsen & Friborg, 2015; Weitz et al., 2015). This study
was also the first to comprehensively investigate associations
between ‘disorder characteristics’ and prognosis independent of
depressive symptom severity. There had been some suggestion
from past studies that the duration of depression might be asso-
ciated with prognosis (Carter et al., 2012; DeRubeis et al., 2014;
Fournier et al., 2009; Lorenzo-Luaces et al., 2020; Noma et al.,
2019) although there were inconsistencies and contradictory find-
ings in past reviews (see online Supplementary Table 2) (Dodd
et al., 2014). In addition, there was limited evidence that
comorbid anxiety (Carter et al., 2012; Chekroud et al., 2016)
and a history of antidepressant use (Chekroud et al., 2016;
Nakabayashi et al., 2018; Saunders et al., 2016) may be associated
with outcomes from antidepressant treatments but perhaps not
other types of treatment. Here, these were found to be associated
with prognosis independent of treatment type, and two novel
prognostic factors were also found: the average duration of anxiety
problems and comorbid panic disorder.
Strengths and limitations
There are a number of strengths of the current study. A large
dataset was assembled with approximately 98% of the participants
in all eligible studies. Over 6000 participants were assessed with
the most commonly used comprehensive measure of depressive
and anxiety disorders in depression RCTs set in primary care:
the (CIS-R), this provided a broad range of prognostic factors
to investigate and removed potential biases in harmonising data
(Siddique et al., 2015; Weitz et al., 2017). All studies recruited
those that had sought treatment in naturalistic, primary care set-
tings. Follow-up rates were generally good and missing data at
follow-up had little influence on the findings. A wide range of
treatments were used within the randomised studies, including
antidepressants, cognitive behavioural therapy of high and low
intensities, physical activity and supportive counselling. Causal
relationships were not the focus of the current study so confound-
ing was not particularly relevant, but adjustments were able to be
made for a number of baseline covariates, adding robustness to
the findings. A variety of methods were adopted to assess out-
comes and these led to very similar findings, further supporting
the conclusions of the current study.
The samples included in this review had been recruited to par-
ticipate in RCTs, and only studies recruiting in the UK met the
inclusion criteria, perhaps due to the use of CIS-R, which may
be less familiar to investigators outside the UK. Although it was
more commonly used than other clinical interviews, it might
have been possible to include studies using those less commonly
used interviews too, and then have conducted subgroup analyses
per-measure to address issues of harmonising biases. That not-
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CIS-R and were conducted outside the UK, and a number of stud-
ies that used other clinical interviews returned in the scoping
searches or full searches for this review, however they often did
not meet other inclusion criteria for this review (Husain et al.,
2014; Patel et al., 2003). The inclusion of only RCTs and only
those that used the CIS-R may have led to a biased sample of
all patients with depression and could limit the generalisability
of the findings. However, 11 of the 12 studies were pragmatic
trials and recruited adults with new episodes of depression, so
the participants should be representative of other depressed
patients presenting to general practitioners/physicians and psy-
chiatrists across the world. Furthermore, 11 of the 12 studies
recruited participants that had actively sought treatment for
depression; the other used a variety of methods including recruit-
ing participants as they sought treatment but also calling those
that had sought treatment for depression over the previous 2
years pre-baseline and asking if they were willing to be rando-
mised to receive treatment for depression, or a placebo (Lewis
et al., 2019). The uniformity of the setting offers an improvement
in the extant literature in which there has been limited informa-
tion about from where participants were recruited (Dal-Ré,
Janiaud, & Ioannidis, 2018). Furthermore, there is nothing to sug-
gest that the samples drawn from UK primary care are substan-
tially different to samples of adults with depression seeking
treatment elsewhere, and the treatments used in the included
studies are common in many countries.
The data on duration were self-reported and relied upon a
retrospective judgement; that is likely to have increased measure-
ment error. It is possible that those with more depressive symp-
toms reported longer durations of illness because of negative
cognitive biases, but adjustments were made for baseline depres-
sive symptoms minimising such bias. In any case, knowing that
reported duration is a prognostic factor might be of clinical
value even if this could be partly influenced by symptom severity
(Lorenzo-Luaces et al., 2020).
Heterogeneity in some of the associations was high when con-
sidering the I2 statistic, in the study protocol it was specified that
sensitivity analyses would be run where I2 was above 75% for all
factors or above 50% for factors that included in the final models
or if there were clear differences between the effects across the
studies included in the IPD. More conservative limits for hetero-
geneity could have been set, but given that none of the sensitivity
analyses substantively changed the findings related to any of the
prognostic indicators and given that all models were run with ran-
dom effects for study, it seems unlikely that this would have had a
meaningful impact on the results presented here.
Implications and conclusions
The differences in prognosis observed here were compared with a
published estimate for the minimally important clinical differ-
ence. Previous study has suggested this is approximately 17.5%
in terms of BDI-II scores (Button et al., 2015). The finding that
one standard deviation increase in baseline depressive symptoms
led to an approximate 31% difference at endpoint therefore sug-
gests that such a change is clinically important. Four additional
factors: the duration of anxiety; duration of depression; comorbid
panic disorder and a history of antidepressant treatment were also
independently associated with poorer prognosis. These depressive
‘disorder characteristics’ are not likely to be associated with clin-
ically important differences when considered alone, but they
might be when considered concurrently. For example, those in
the ‘high severity’ category of all four factors had outcome symp-
tom scores 36% higher than those in the lowest category.
Although this only applied to a small proportion of the patients
more than 86% in this sample were in the ‘high severity’ category
on at least two of these factors. It may therefore be important for
clinicians to assess for all of these factors routinely, pre-treatment.
All could be easily captured in clinic or with brief online ques-
tionnaires. Assessment of these factors would improve clinicians’
ability to predict prognosis.
Future research should ascertain what other factors are
informative for prognosis after accounting for depressive ‘disorder
characteristics’, whether effects are informative for treatment
selection, and whether earlier or more intensive treatments, and
more frequent reviews for those likely to have poor outcomes
help mitigate these problems, and conversely whether more con-
servative management is sufficient for those with better
prognoses.
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